NCT06738862

[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 55 (actual)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 45 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The main objective of this study is to establish a standardized method for \[18F\] - FD17 PET imaging in α-synucleinopathy patients, and to analyze its physiological distribution in healthy individuals as well as its pathological distribution in α-synucleinopathy patients, including Parkinson's disease (PD), multiple system atrophy (MSA), and idiopathic rapid-eye-movement sleep behavior disorder (iRBD). Specifically, \[18F\] - FD17 PET imaging focuses on evaluating the deposition of α-synuclein and exploring the diagnostic value of \[18F\] - FD17 PET in PD, MSA, and iRBD patients. In addition, for PD, MSA and RBD patients, dopamine transporter(DAT)-PET imaging was performed to evaluate the distribution and density of DAT in brain. The study aims not only to clarify the specific binding mode of the imaging agent in different α-synucleinopathies, but also to evaluate its efficacy and potential application prospects in early diagnosis , providing new methods for the diagnosis and treatment of neurodegenerative diseases. This study is expected to contribute to early pathological detection and accurate diagnosis in clinical practice.

Conditions

• α-synucleinopathy
• Parkinson's Disease (PD)
• Multiple System Atrophy
• Rapid Eye Movement Sleep Behavior Disorder
• PET

Interventions

Type	Name	Description
OTHER	PET	\[18F\] - FD17 PET imaging

Timeline

• Start date: 2024-12-14
• Primary completion: 2025-12-25
• Completion: 2025-12-25
• First posted: 2024-12-18
• Last updated: 2026-03-05

Locations

1 site across 1 country: China